X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA PIRAMAL ENTERPRISES PLETHICO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -1.1 8.3 - View Chart
P/BV x 0.0 1.5 1.1% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 PLETHICO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-18
PLETHICO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3953,083 12.8%   
Low Rs311,902 1.6%   
Sales per share (Unadj.) Rs604.4589.7 102.5%  
Earnings per share (Unadj.) Rs32.5284.0 11.4%  
Cash flow per share (Unadj.) Rs51.3310.5 16.5%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs473.61,467.0 32.3%  
Shares outstanding (eoy) m34.08180.27 18.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.44.2 8.3%   
Avg P/E ratio x6.68.8 74.8%  
P/CF ratio (eoy) x4.28.0 51.7%  
Price / Book Value ratio x0.51.7 26.5%  
Dividend payout %08.8 0.0%   
Avg Mkt Cap Rs m7,262449,332 1.6%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m1,59619,881 8.0%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m20,598106,310 19.4%  
Other income Rs m3862,595 14.9%   
Total revenues Rs m20,984108,906 19.3%   
Gross profit Rs m2,81851,599 5.5%  
Depreciation Rs m6424,773 13.5%   
Interest Rs m1,59329,783 5.3%   
Profit before tax Rs m96919,638 4.9%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-28,764 0.5%   
Profit after tax Rs m1,10751,203 2.2%  
Gross profit margin %13.748.5 28.2%  
Effective tax rate %-14.3-146.5 9.8%   
Net profit margin %5.448.2 11.2%  
BALANCE SHEET DATA
Current assets Rs m18,877118,154 16.0%   
Current liabilities Rs m11,896462,260 2.6%   
Net working cap to sales %33.9-323.7 -10.5%  
Current ratio x1.60.3 620.8%  
Inventory Days Days3627 135.2%  
Debtors Days Days19847 425.1%  
Net fixed assets Rs m9,861113,727 8.7%   
Share capital Rs m341361 94.5%   
"Free" reserves Rs m12,331264,093 4.7%   
Net worth Rs m16,139264,454 6.1%   
Long term debt Rs m4,706242,206 1.9%   
Total assets Rs m33,146726,834 4.6%  
Interest coverage x1.61.7 96.9%   
Debt to equity ratio x0.30.9 31.8%  
Sales to assets ratio x0.60.1 424.9%   
Return on assets %8.111.1 73.1%  
Return on equity %6.919.4 35.4%  
Return on capital %12.310.3 119.2%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40215,110 29.1%   
Fx outflow Rs m3,1844,298 74.1%   
Net fx Rs m1,21910,813 11.3%   
CASH FLOW
From Operations Rs m2,437-159,666 -1.5%  
From Investments Rs m-6,265-17,677 35.4%  
From Financial Activity Rs m2,490186,503 1.3%  
Net Cashflow Rs m-1,3379,364 -14.3%  

Share Holding

Indian Promoters % 82.7 52.9 156.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 4.0 107.5%  
FIIs % 5.5 26.6 20.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 16.5 45.5%  
Shareholders   10,665 93,274 11.4%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - SUN PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS